Intellia Therapeutics Inc Revenue Growth Rates (NTLA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Intellia Therapeutics Inc   (NASDAQ: NTLA)
 

NTLA's Revenue Growth by Quarter and Year

Intellia Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NTLA/growth
https://api.csimarket.com/api/v1/companies/NTLA/fundamentals
https://api.csimarket.com/api/v1/companies/NTLA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NTLA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 7.16
2nd Quarter June 7.66
1st Quarter March 15.05
FY 29.87

NTLAs Annual Revenue
Intellia Therapeutics Inc 's Revenue in the fiscal year 2025 $ 67.67 millions
Intellia Therapeutics Inc 's Revenue in the fiscal year 2024 $ 57.88 millions
Intellia Therapeutics Inc 's Revenue in the fiscal year 2023 $ 36.28 millions
Intellia Therapeutics Inc 's Revenue in the fiscal year 2022 $ 52.12 millions
Intellia Therapeutics Inc 's Revenue in the fiscal year 2021 $ 33.05 millions




NTLA Revenue third quarter 2026 Y/Y Growth Comment
Intellia Therapeutics Inc reported drop in Revenue in the third quarter 2026 by -48.02% to $ 7.16 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Intellia Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 44.7%.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue growth. While Intellia Therapeutics Inc ' s Revenue meltdown of -48.02% ranks overall at the positon no. 3739 in the third quarter 2026.


NTLA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -48.02 %
2nd Quarter June -46.25 %
1st Quarter March -9.5 %
FY   -

Financial Statements
Intellia Therapeutics Inc 's third quarter 2026 Revenue $ 7.16 millions NTLA's Income Statement
Intellia Therapeutics Inc 's third quarter 2025 Revenue $ 13.78 millions Quarterly NTLA's Income Statement


NTLA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -6.49 %
2nd Quarter June -49.1 %
1st Quarter March -34.62 %
FY (Year on Year)   -


Back to NTLA Growth rate Comparisons >> Back to NTLA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #519
Overall #3739

Revenue Y/Y Growth Statistics
High Average Low
249.75 % 44.7 % -67.58 %
(Mar 31 2017)   (Sep 30 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #519
Overall #3739
Revenue Y/Y Growth Statistics
High Average Low
249.75 % 44.7 % -67.58 %
(Mar 31 2017)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Intellia Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
136.69 % 8.51 % -75.96 %
(Jun 30 2016)  


NTLA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Intellia Therapeutics Inc disclosed decline in Revenue from the second quarter by -6.49% to $ 7.16 millions, from $ 7.66 millions achived in the previous reporting period.

But that's not important problem, as Intellia Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Intellia Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3694.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #531
Overall #3694
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #531
Overall #3694
Revenue Q/Q Growth Statistics
High Average Low
136.69 % 8.51 % -75.96 %
(Jun 30 2016)  


NTLA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Intellia Therapeutics Inc disclosed decline in Revenue from the second quarter by -6.49% to $ 7.16 millions, from $ 7.66 millions achived in the previous reporting period.

But that's not important problem, as Intellia Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Intellia Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3694.


Intellia Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 52.89
Y / Y Revenue Growth (TTM) -8.07 %
Year on Year Revenue Growth Overall Ranking # 1103
Seqeuential Revenue Change (TTM) -11.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 1054


Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2026 Intellia Therapeutics Inc reported a decrease in Revenue by -8.07% year on year, to $53 millions, compare to the 12.58% growth at Jun 30 2026.

In the Healthcare sector 206 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 843 to 1103.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 207
Overall # 1103

Revenue TTM Y/Y Growth Statistics
High Average Low
220.08 %
 32.56 %
-57.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 203
S&P 500 # 1054
Cumulative Revenue growth Comment
For the 12 months ended Sep 30 2026 Intellia Therapeutics Inc reported a decrease in Revenue by -8.07% year on year, to $53 millions, compare to the 12.58% growth at Jun 30 2026.

In the Healthcare sector 206 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 843 to 1103.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 207
Overall # 1103

Revenue TTM Y/Y Growth Statistics
High Average Low
220.08 %
32.56 %
-57.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 3
Sector # 203
S&P 500 # 1054




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NTLA's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Intellia Therapeutics Inc Revenue Growth Rates (NTLA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Intellia Therapeutics Inc (CIK 1652130).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-449862
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Intellia Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.